- Brand name: Ceralifimod (Merck Serono)
- Route of Administration: Oral
- Emerging treatment for: RRMS
- Status: In Phase II of clinical trials
ONO-4641 reduces the infiltration of lymphocytes into the CNS.
How it Works
ONO-4641 binds to Sphingosine-1-phosphate receptor. ONO-4641 inhibits lymphocytes from exiting lymphatic tissue, decreasing their presence in the periphery and suppressing their infiltration into the CNS.
Research and Results
A phase II trial (DreaMS) examined the effect of 0.05mg, 0.1mg, 0.15mg of ONO-4641 or placebo, given once daily, on brain lesions. After 26 weeks, treated groups showed a significant reduction in new or enlarged brain lesions. An ongoing phase II extension of DreaMS is scheduled for completion in 2016.
Adverse Effects Reported
Adverse effects are unclear. More clinical trial data is required.
Komiya, T et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol. 2013; 171: 54-62.